<International Circulation>: Our audience is primarily Chinese. They would be interested to know how ACC has approached the Asian side of the world. 

  《国际循环》：我们杂志的读者主要是中国人，他们可能会感兴趣于ACC将如何进入亚洲？

    Prof Crawford: We invite attendees from all over the world. We have specific sessions designed for our international colleagues. We have the international lunches which take place on Sunday and Monday and we have 18 of them this year. China is one of the 18 that is holding an international lunch. Some of the US experts that they want to hear from are invited to that luncheon followed by a discussion. Usually there is a topic chosen and experts on that topic attend and together with their counterparts from China， they have a lively discussion perhaps about differences in management. For instance， at this year’s Chinese symposium， we will be discussing the use of diuretics as first line treatment for hypertension which is very common practice in China. The fact that the United States is moving away from that and going more often to calcium channel blockers and angiotensin receptor blockers or angiotensin converting enzyme inhibitors as first line therapy is obviously of interest.

    Crawford教授：这次我们邀请了来自世界各地的与会者。我们为国际的同事专门准备具体的会议。周日和周一我们有国际午餐会，今年共有18个国家参加午餐会。中国就是参加国际午餐会的18个成员之一。美国专家应邀参加了讨论之后的午餐会。通常情况是选定一个主题，关于该主题的专家与来自中国的同行共同参加。他们可以对于治疗方案的差异性进行现场的讨论。例如，在今年的中国研讨会，我们将会讨论利尿剂作为一线药物治疗高血压的应用，这一作法在中国是非常普遍的。事实上在美国正在抛弃这一做法，更多的采用钙通道阻滞剂和血管紧张素受体阻滞剂或血管紧张素转换酶抑制剂作为首选药物显然是其趋向所在。